approach upgrad outperform
adjust number upgrad outperform perform
pt believ addit savvi veteran ceo
daniel day announc year-on-year sale growth import
mid/late-stag clinic readout bud franchis inflamm filgotinib
nash selonsertib nash combin trial could start re-rat biotech
bellweth name among cheapest large-cap biotech
stretch compani lost almost top line slow hcv sale
believ gilead pois get mojo back deliv fundament mid/
late-stag pipelin progress burgeon acquisition/licens heighten
mr day previou experi oncolog bellweth roch
conclus ceo search decemb focus
mr day bring tabl believ meet criteria scientif
mind patient-centr ceo understand chang reimburs
landscap help manag grow institut complex
employe desir ex-u growth sale
roch mr day part activ team acquisition/licens
see exhibit strategi review state thought
focu diseas high unmet need mortal morbid highli clinic
signific data believ real possibl synergi especi
sub-optim oncolog franchis current mostli cell therapi
analyz recent product sale perform convers
manag believ compani pois restart y/i sale growth
stretch sale decreas abl maintain
margin also potenti grow non-gaap earn albeit
lower convict could invest year
drive re-rat import readout filgotinib finch finch nash
monotherapi selonsertib combin atla interim could
solidifi two pillar growth high convict best-in-class
filgotinib increas convict nash franchis
risk upgrad thesi continu weak busi fundament
sale growth disproportion depend hiv busi
y/i growth model anoth risk signific safeti signal
filgotinib phase trial and/or failur mid/lat stage selonsertib
combin nash trial
year price histori
gilead develop commerci
area
includ treatment hiv/aid liver
diseas cancer inflamm
analyst certif import disclosur see disclosur
hcv sale declin slowli stabil
hiv busi launch taf-bas regimen bic/f/taf
make hiv solid growth busi
yescarta axi-cel launch across us eu meet
expect sale
nash franchis lead product selonsertib approv
market
cardiovascular/oth busi sale reduc
due gener competit
non-gaap oper margin declin
rebound
upgrad gilead outperform perform
believ addit savvi industri veteran
daniel day new ceo announc year-
on-year sale growth import mid/late-stag clinic
readout bud franchis inflamm filgotinib
nash selonsertib nash combin trial could start re-
rate biotech bellweth name among cheapest
phase data pbc yescarta two-
year follow-up data tirabrutinib phase combo data r/
selonsertib phase data nash
selonsertib phase data nash
phase data cle sjogren syndrom
complet list catalyst exhibit
hcv sale trough next quarter stable/up
patient diagnos treat
hiv busi outperform expect
yescarta us/eu launch beat reduc expect provid
abl start grow margin onward
hcv busi continu declin precipit rate near
hiv busi growth minim best next two five year
yescarta us/eu launch underperform reduc expect due
car-t side-effect manufactur reimburs concern
nash franchis gain traction clinic data
mediocr best even among nash patient fibrosi
employ composit valuat methodolog biotechnolog compani util forward price-to-earnings multipl net present valu
adjust non-gaap estim earn sinc biotechnolog sector high-growth/high-expect sector aim rank
target compani base qualiti sale and/or earn growth versu peer group
peer index nbi index expect earn growth next year expect
appli lower termin multipl adj ep due lower sales/earn growth trajectori versu peer group
appli discount rate gild valuat peer group averag
risk thesi follow
continu see sale declin margin deterior
mid/lat stage pipelin project inflamm filgotinib nash selonsertib combin trial nash unsuccess
new ceo oday abl execut acquisition/licens strategi help fundament strengthen faster expect
employ composit valuat methodolog biotechnolog compani util
forward price-to-earnings multipl net present valu adjust non-gaap estim
earn sinc biotechnolog sector high-growth/high-expect sector aim
rank target compani base qualiti sale and/or earn growth versu
peer group
pt assumpt indic tabl
peer index nbi index expect earn growth
next three five year expect
appli lower termin multipl adj ep due lower
sales/earn growth trajectori versu peer group
appli discount rate gild valuat vs peer group averag
risk thesi follow
continu see sale declin margin deterior
mid/lat stage pipelin project inflamm filgotinib nash
selonsertib combin trial nash unsuccess
new ceo daniel oday abl execut acquisition/licens strategi
help fundament strengthen faster expect
part turmoil face due hire new ceo
veteran john milligan chairman john martin also ex-ceo announc
departur earn call decis creat uncertainti among
investor futur direct compani
potenti futur leader endlessli debat popular media
convers investor note daniel oday mention
potenti pick media report among candid
believ move hire daniel oday ceo begin savvi one
mr oday fulfil mani criteria depart ceo john milligan indic
import hire process
understand increas complex reimburs landscap
understand institut complex employe grow
grow ex-u busi total sale
understand commerci launch execut
believ move made boost commerci leadership corpor
develop activ bode well mr oday gild futur compani fill
current strong leadership financ scientif affair proven industri
believ mr oday also instrument buf gild sub-optim
oncolog franchis current best-in-class cell therapi product kite acquisit
believ hint futur direct gild interest oncolog
role roch sw pharmaceut ceo recent move
also believ mr oday welcom addit gild corpor
develop activ ceo prolif acquisition/busi develop
strategi sw
exhibit sw acquisition/busi develop activ ceo daniel oday tenur
time deal typenames up-front hcv drug dianostica mileston eurhemostati platelet function austria hemostati thrombosi cardiovascular offer failedillumina schoolaustim spectrum disord renew sysmex japan hematolog blood urin etc healthcar japan metabol therapeuticsfragil syndrom fx austim spectrum alpha rightsgalaxi usdantibodi cancer ventur incept sciencedrug discoveri incub sensorineur hear icin initi imi platoform unit ten compani academ system scienc japan gene sequenc autom pcr usdoctreolin acromegali neuroendocrin tumorstim deal typenames up-front hcv drug roboticsautom dna sampl in-vitro cell cultur institut quant biosciencesfund earli stage life scienc ical contigentusdhematolog test agreementicin patent poolcytomegaloviru dna immunotherapi prostat cancer rightspolyphor ltd infect caus pseudomona germani usdimmunotherpai gastric lung prostat biolog milestoneschfoncolog corpor usdparkinson system scienc japan nsgene sequenc autom pcr limit acquir later usdantibiot treat infect gram-neg usdmolecular diagnosticstim deal typenames up-front hcv drug genom sa inhibitor oncolog haematolog renew hitachi high-technolog corporationnsworkflow autom solut medic technolog usddna scienc versant venturesnssmal molecul remyelin therapi patient multipl pharmaceuticalnsrecombin follicle-stimul hormon human rfsh usdhormon receptor-posit breast up-front mileston small molecul disease-modifi therapi myoton muscular dystrophi usd lock nucleic acid lna platform rna-target pulmonari usdnon-invas prenat test nipt cell-fre dna cfdna acquisitionavansci biotissu dissect gmbh usdbi-specif icinedetail linkusdoncolog rightsmeiji up-front mileston usdbeta-lactam antibiot outperform
time deal typenames up-front hcv drug genom sa inhibitor oncolog haematolog muscular atrophi incorporatedremot monitor manag chronic diseas medicin inc detail agreementbiochem sequenc arthriti fibrot rais diabet nsusdlaboratori busi solut select cns-activ tyrosine-kinas inhibitortim deal typenames up-front hcv drug healthcarensindividualis regulatori prime therapeuticsnsimmuno-oncolog protein previous atrophi ga dri age-rel macular degener inc
select commentari daniel oday roch
question tim race competitor bank
move gener strategi bought flatiron compani
obvious make much profit today want keep line
competitor alreadi use use could help us understand see
compani bring return block competitor use
technolog go forward somehow identifi compani
go rapid evolut profit realli bring billion
respons daniel day ceo roch pharma divis
state mayb add coupl thing flatiron go ocrevu
shionogi ye think well captur severin sat flatiron
last year relationship know mani year
insight strategi board perspect basic said
compani continu success independ acquisit
roch assum creat independ autonomi acceler
significantli mission flatiron
acceler import mean privat compani could invest
certain amount roch group given object synergi us
life scienc provid gain thought acceler realli import
expect busi first expect busi
success think think much potenti track
independ compani want encourag acceler
stand-alone busi provid servic oncolog custom provid life
scienc compani number one
number two get industri get world
lead real world data databas allow us thing differ
today oncolog everyth look differ treatment regimen get
reimburs approv market mean possibl phase clinic trial
everi differ treatment regimen might appropri reimburs
author around world use robust data abl get
reimburs faster think real benefit also acceler
clinic trial hypothesi clinic trial design bring trial patient
commun oncolog studi potenti either supplement replac
speed clinic trial use real world data control arm instead necessarili
enrol everi time sponsor compani new medicin replic
standard care control arm
think fda larg extent discuss think
better way way cours success leverag
compani success leverag
unbias standard creat regulatori author
acceler contrari block compani creat
fire wall allow provid life scienc compani confid
privaci data make sure busi model continu
good experi way mean firewal place
year improv relationship life scienc counterpart
year know work overal
manag discuss daniel day ceo roch pharma divis
final think quit characterist strategi look bolt-on
acquisit think could add signific valu ignyta entrectinib
particular one medicin medicin pan-tumor activ fairli rare
mutat remind cancer rare mutat similar alecensa
strong product us
question tim anderson competitor bank
thank question confirm bolt-on realli primarili
continu look avastin wonder biosimilar mitig
strategi like expect advanc sub-queu formul
point like done product
respons daniel day ceo roch pharma divis
ye tim thank question think noth chang avastin
strategi term navig biosimilar landscap mean said think
vanucizumab one mani product establish superior avastin
said mitig strategi around avastin although differ
necessarili respect mabthera rituxan look
one-to-on replac strategi despit advanc like avastin realli
go base upon combin strategi immunotherapi strategi across
seven differ diseas stage lie today go
still combin avastin may without avastin combin
sub-queu strategi avastin someth pursu
stage remind got immunotherapi got clinic
trial go right combin trial
signific program behind colon lung renal cell carcinoma area
avastin today also breast realli overal approach
like replac avastin immunotherapi differ combin without avastin
move forward
question andrew baum competitor bank
first interest recent thought roch deserv could say
think focus deal billion less memori could
remind us great
respons daniel day ceo roch pharma divis
second question regard realli noth chang
strategi remain focus bolt-on acquisit get specif product
technolog round portfolio know focus realli lot
earli stage deal later stage deal diagnost side far
pharma concern except intermun realli quit number
transact earli stage preclin earli develop far later stage
opportun concern rare start typic make
econom never come conclus deal would realli
creat mainli sharehold see much chang go forward
know complet mega merger start right
manag discuss daniel day ceo roch pharma divis
slide return cancer immunotherapi remind slide
today in-hous cancer immunotherapi asset clinic slide
usual show immunotherapi trial cycl say quarter-
one two addit compound test combin
atezolizumab extern collabor varieti extern collabor
complement broad intern portfolio announc
collabor janssen kite first quarter year continu
round atezolizumab trial program trial on-going cancer
question unknown
second one relat effici measur highlight also
partnership collabor rememb year ago gave color
around sale bit think pipelin term partnership
stand goal target
respons daniel day ceo roch pharma divis
thank sandra briefli noth chang innov strategi
mean rich pipelin cognizantli awar
innov happen outsid roch wall
portfolio within partner someon els
differ partnership allianc acquisit last year predominantli preclin
phase phase stage activ associ term bring molecul
and/or field combin medicin partner key compani
continu would say extrem import part strategi
oncolog pull initi list oncology-focus compani could
constitut list target acquisit and/or busi develop pleas refer
appendix section
initi list potenti target believ gild criteria base
previou acquisitions/d focu product
address area high unmet need diseas popul high
produc clinic signific result clinic trial result clinic
signific versu statist signific
best-in-bre product kite pharma pharmasset acquisit
model restart product sale growth y/i
model base follow assumpt
hiv revenu grow y/i us growth declin ex-u
revenu due on-going loss exclus loe european
market viread
believ us sale continu power biktarvi
launch on-going success truvada prep potenti
convers eu market ftc/taf base regimen
biktarvi approv eu
descovi ftc/taf base regim made gild us hiv
prescript volum earlier year expect
trend continu eu see exhibit initi trend
switch compet regim stronger eu us
switch total switch us vs switch germani
hiv treatment truvada prep continu show strength
patient therapi
treatment end
acceler trend patient addit truvada prep
increas focu descovi discov phase trial evalu
descovi pre-exposur prophylaxi prep hiv trial
expect complet earli late
truvada loe septemb per file
hcv assum sale vs
bloomberg consensu respect
believ hcv franchis near trough
also recent move sell author gener version
hcv medic epclusa harvoni believ strategi
could help gain market share certain portion medicar
part market state medicaid organ small reimburs
group negoti discount rebat negoti
adjust yescarta number
respect complex reimburs
environ logist car-t therapi administr make
believ slightli slower expect yescarta
sale sign therapeut class even yescarta
rather complex align reimburs infus
structur pleas refer exhibit appendix section
overal model small sale declin return
growth see model
remind investor season downward effect
product sale mask hcv roller-
coaster last year model sale
yearli sale line previou research large-cap
season publish earlier year
addit see stronger sale growth due
biktarvi ex-u uptak continu truvada prep uptak
model slight earn growth y/i non-gaap ep growth vs
sale growth adjust oper margin vs
lower convict
import late-stag readout nash see catalyst exhibit
on-going prepar mid/lat stage clinic trial potenti launch sale prep
inhibitor filgotinib variou inflammatori condit believ
invest year
see non-gaap margin trough
current note maintain close peer-group
margin last year time lost almost peak
sale revenu quit achiev speak
gild strength disciplin fiscal respons view
nbi index sale per share
pipelin readout import
increas sale incom ceo abil encourag greater
acquisitions/partnership especi oncolog believ import late-stag
readout pipelin nash filgotinib could also re-rat name via multipl
believ filgotinib potenti best-in-class
previous written howev additon human safeti testicular toxic see
believ anoth patient year worth safeti data need
declar filgotinib winner crown variou inflammatori condit
oral jak inhibitor ra develop first pan-jak
inhibitor tofacitinib approv ra late next oral jak-
inhibitor baricitinib approv ra
interestingli approv lower dose fda cite
convinc efficaci benefit yet increas safeti risk higher dose
confer greater benefit safeti disclosur indic littl addit risk
